Presentations
What is a Presentation?Filters
Jamboree presentation
Creators: Daniel Lill, Viktor Makarenko, Ursula Klingmüller, Jens Timmer
Submitter: Daniel Lill
Download
Poster presented at Hünfeld Retreat 2018
Creators: André Homeyer, Seddik Hammad, Lars Ole Schwen, Steven Dooley, Andrea Schenk, Uta Dahmen, Henning Höfener, Yan Gao
Submitter: Lars Ole Schwen
Presentation at 20. Chirurgische Forschungstage, Minisymposium Systembiologie der (Fett-)Leber und Implikationen für chirurgische Forschung, Magdeburg 2016
Creator: Lars Ole Schwen
Submitter: Lars Ole Schwen
I gave this talk at the SBMC 2018 in Bremen (Session: Systems Medicine & Clinical applications)
Creator: Christian Holland
Submitter: Christian Holland
Creators: Tim Johann, Dirk Drasdo, Stefan Hoehme, Paul Van Liedekerke, Johannes Neitsch
Submitter: Tim Johann
Computational models complement experimental methods in the analysis of tissue organization processes, and play an increasingly important role in systems biology and systems medicine. Creating and parameterizing mathematical models for the simulation of biological tissue dynamics at multiple scales is still a complex and resource-consuming task, which necessitates skills in diverse scientific disciplines. The software TiSim was conceived to facilitate programming, integration and deployment of ...
Creators: Tim Johann, Jieling Zhao, Stefan Hoehme, Dirk Drasdo, Andreas Buttenschön, Noémie Boissier, Géraldine Cellière, Paul Van Liedekerke, Johannes Neitsch
Submitter: Tim Johann
Poster at SBMC 2018
Creators: Lars Ole Schwen, Lars Kuepfer, Ahmed Ghallab, Jan Hengstler, Tobias Preusser, Raymond Reif
Submitter: Lars Ole Schwen
Creators: Tim Johann, Dirk Drasdo, Ayham Zaza, Jieling Zhao, Paul Van Liedekerke
Submitter: Tim Johann
The transforming growth factor (TGF)-β has been identified as a master regulator of liver fibrogenesis. Thus, targeting TGF-β1 pathway might modulate chronic liver disease (CLD) development and/or progression in murine model. Galunisertib (Ly2157299), already in clinical studies phase II, is an oral small molecule targeting TGF-β type I receptor (ALK-5).
Creators: Seddik Hammad, Julia Werle
Submitter: Seddik Hammad
